Ozempic Pills Market Surge: Analyzing Oral Peptide Efficacy, Brand Rivalry & Supply Chain Trends
Title: Ozempic Pills Market Surge: Analyzing Oral Peptide Efficacy, Brand Rivalry & Supply Chain Trends Abstract: The oral GLP-1 peptide market is surging, driven by Novo Nordisk’s Rybelsus (semaglutide) and emerging competitors like Eli Lilly’s orforglipron. Oral peptides offer superior patient compliance versus injectables but suffer from low bioavailability ( 1%) requiring high doses. Brand rivalry intensifies around efficacy (HbA1c reduction up to 1.5%) and side-effect profiles. Supply chain bottlenecks persist due to specialized cold-chain logistics and stringent FDA/EMA certifications. Key selection criteria include purity (>98%), third-party lab testing (COA), and manufacturer GMP compliance. Market trends project a CAGR of 12.5% through 2030, with oral formulations capturing 30% of the peptide obesity market.